Table 1 Patients characteristics.

From: Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial

 

All

Vx-001

Placebo

No of patients

%

No of patients

%

No of patients

%

190

 

89

 

101

 

Sex

   Males

132

69.5

60

67.4

72

71.3

   Females

58

30.5

29

32.6

29

28.7

Age

   >65 years

99

52.1

45

50.6

54

53.5

   <65 years

91

47.9

44

49.4

47

46.5

Histology

   NSQ

114

60.0

55

61.8

59

58.4

   SQ

72

37.9

34

38.2

38

37,6

   Mixte

4

2.1

0

0.0

4

4,0

Response to previous treatment

   OR

88

46.3

36

40.4

52

51.5

   SD

102

53.7

53

59.6

49

48.5

ECOG

   0

75

39.5

33

37.1

42

41.6

   1

115

60.5

56

62.9

59

58.4

Smoking status

   Never

25

13.2

10

11.2

15

14.9

   Smokers

165

86.8

79

88.8

86

85.1

   Heavy smokers (>25 years)

128

67.4

62

69.7

66

65.3

   Light smokers (<25 years)

35

18.4

17

19.1

18

17.8

   Missing

2

1.1

0

0,0

2

2.0